ClinicalTrials.gg
CompletedNCT03475459Updated Jun 28, 2018

Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7)

A Phase 1 interventional study of NPC-15 and/or Placebo in Qt Interval, Variation in, sponsored by Nobelpharma. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-28.

Sponsored by Nobelpharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
20 Years to 45 Years
Sex
All
01

Study summary

A study to assess the QTc prolongation effect of NPC-15 (melatonin 8mg or 16mg)

Read the detailed description

This study is a single center, open label, dose escalation trial to evaluate prolongation effect on QT interval of NPC-15 (melatonin 8mg or 16mg).

The trial compose of 3 periods; During the each period, eligible volunteers wll be administered placebo, NPC-15 4g (melatonin 8mg) and NPC-15 8g(melatonin 16mg) as a sequential manner.

02

Conditions studied

  • Qt Interval, Variation in

Keywords

  • QTc prolongation effect
03

In context

Lead sponsor

Nobelpharma is the lead sponsor of 34 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject with ≥ 17.6 kg/m2 and \< 30.0 kg/m2.
  • Subject who falls asleep at between 21:00 and 25:00 and wakes up at between 5:00 and 9:00 during 1 week prior to the first study drug administration.
  • Subject who is able to comply with the study requirements during the study period.

Exclusion criteria

Exclusion Criteria:

  • Subject with interval greater than 450 ms in male or greater than 470 ms in female on the 12-lead (ECG), or with ECG abnormalities in other findings.
  • Subject who has a family history of Torsades de Pointes (TdP) or long QT syndrome.
  • Subject who has a history of or allergies to melatonin or ramelteon.
  • Subject who has a current or a history of disease which is considered inappropriate to be involved in the study, or who has any current disease to require treatments.
  • Subject who received any non-prescription or prescription drug within 2 weeks prior to the first study drug administration.
  • Subject who received any product containing St Jones Wart or any supplement containing melatonin within 4 weeks prior to the first study drug administration.
  • Subject who has a history of smoking habit or was possibly exposed to passive smoking on a daily basis within 24 weeks prior to the first study drug administration.
  • Subject who, in the opinion of the investigator or sub-investigator, is unsuitable to be involved in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    study drug

    Study drug (NPC-15 and/or Placebo ) will be orally administered once with 200 ml of water at 20:00 on the first days of Period I, Period II and Period III.

    Drug: NPC-15 and/or Placebo

Interventions

  • DrugNPC-15 and/or Placebo

    The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)

    Also known as: Melatonin and/or Placebo

06

What researchers measure

Primary outcomes

  1. Time matched, baseline-adjusted change in Fridericia-corrected QTc (QTcF) intervals

    QTcF interval is a common endpoints to evaluate arrhythmogenic effect of test drug

    Time frame: Day1 and Day2 of each periods (3 periods)

Secondary outcomes

  1. Serum melatonin concentration

    NPC-15 is a preparation containing melatonin , therefore the change in blood concentration of melatonin is useful to evaluate the QTc prolongation effect of NPC-15.

    Time frame: Up to 12 hours post dose in each period (3 periods)

  2. Maximum drug concentration (Cmax) of melatonin

    NPC-15 is a preparation containing melatonin , therefore pharmacokinetic parameter is useful to evaluate the QTc prolongation effect of NPC-15.

    Time frame: Up to 12 hours post dose in each period (3 periods)

  3. Maximum drug concentration time (Tmax) of melatonin

    NPC-15 is a preparation containing melatonin , therefore pharmacokinetic parameter is useful to evaluate the QTc prolongation effect of NPC-15.

    Time frame: Up to 12 hours post dose in each period (3 periods)

  4. Area under the blood concentration time curve (AUC) of melatonin

    NPC-15 is a preparation containing melatonin , therefore pharmacokinetic parameter is useful to evaluate the QTc prolongation effect of NPC-15.

    Time frame: Up to 12 hours postdose in each period (3 periods)

  5. Terminal elimination rate constant (λz) of melatonin

    NPC-15 is a preparation containing melatonin , therefore pharmacokinetic parameter is useful to evaluate the QTc prolongation effect of NPC-15.

    Time frame: Up to 12 hours post dose in each period (3 periods)

  6. Mean residence time (MRT) of melatonin

    NPC-15 is a preparation containing melatonin , therefore pharmacokinetic parameter is useful to evaluate the QTc prolongation effect of NPC-15.

    Time frame: Up to 12 hours postdose in each period (3 periods)

  7. Elimination half-life (t1/2) of melatonin

    NPC-15 is a preparation containing melatonin , therefore pharmacokinetic parameter is useful to evaluate the QTc prolongation effect of NPC-15.

    Time frame: Up to 12 hours post dose in each period

  8. Clearance (CL) of melatonin

    NPC-15 is a preparation containing melatonin , therefore pharmacokinetic parameter is useful to evaluate the QTc prolongation effect of NPC-15.

    Time frame: Up to 12 hours post dose in each period (3 periods)

  9. Volume of distribution (Vd) of melatonin

    NPC-15 is a preparation containing melatonin , therefore pharmacokinetic parameter is useful to evaluate the QTc prolongation effect of NPC-15.

    Time frame: Up to 12 hours postdose in each period (3 periods)

  10. Adverse Events

    All events that emerge during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

    Time frame: Up to 36 hours post dose of Period III

07

Study locations

1 site
  • SOUSEIKAI Hakata Clinic
    Fukuoka, 8120025, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Apr 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2018
First posted
Mar 23, 2018
StartActual
Apr 3, 2018
Primary completionActual
Apr 29, 2018
CompletionActual
Apr 29, 2018
Last update
Jun 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03475459
Lead sponsor
Nobelpharma
Responsible party
Sponsor
First posted
Mar 23, 2018
Start date
Apr 3, 2018
Primary completion
Apr 29, 2018
Completion
Apr 29, 2018
Last update
Jun 28, 2018

Study contacts

Masaharu Hayashi, MD, PhD
principal investigator · Shukutoku University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion